- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06274359
Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities
Digital Storytelling to Reduce Pediatric Influenza Vaccination Disparities: A Pilot Pragmatic Trial
Study Overview
Detailed Description
Study Aim: To (a) assess acceptability, appropriateness, and feasibility of the digital storytelling (DST) intervention, and (b) estimate a pilot effect size of the intervention, via a Pragmatic Trial in 2 clinics in historically Black neighborhoods.
Overview: A pilot pragmatic trial of a DST intervention in caregivers of children 6 mo. to 5 yrs. (n = 200) receiving care at two clinics in historically Black neighborhoods in Denver, CO during one influenza season (10/1/24-3/30/25), assessing pragmatic outcomes and pilot effectiveness with mixed methods.
Setting & Design: The investigators will pilot the intervention at 2 Denver Health primary care clinics in historically Black neighborhoods. These clinics serve >3,000 empaneled Black children and provided >6,000 influenza vaccines to children in 2020-21. Caregivers will be eligible if their child is empaneled (i.e., had 1 well child visit in last 18 months), will be 6 months to 5 years old during the upcoming influenza season (10/1 to 3/30), and has no medical contraindications to vaccination. The investigators will exclude caregivers whose first language is not English, as digital stories will be narrated in English, or are younger than 18 years. A research assistant will recruit caregiver-child dyads from May 1, 2024 to September 30, 2024 in clinic waiting rooms. Caregivers will complete a survey with demographic and vaccine hesitancy items and provide their cell phone number and e-mail address for intervention purposes.
Intervention Description: While this work is highly emergent in nature and exact implementation details are subject to stakeholder refinement, the investigators anticipate the following structure. On October 1st, dyads will be randomized to intervention or control groups (1:1 ratio). Intervention caregivers will receive a series of 6 monthly texts with embedded digital stories and accompanying health messaging. Control caregivers will receive usual care.
Outcomes: Our primary aim will be child influenza vaccination status, extracted from our electronic health record (EHR) at season's end (March 30, 2025). Caregivers assigned to the intervention group (n = 100) will receive a follow-up survey with validated measures assessing their perceptions of intervention feasibility, acceptability, and appropriateness.
Covariates: Caregiver independent variables will include age, sex (as a biological variable), education, income, race, ethnicity, insurance status, and scaled vaccine hesitancy score (range: 0-100, with 0 indicating not at all hesitant). The investigators will assess caregivers' perceptions of DST feasibility, appropriateness, and acceptability with validated questions on a 5-point Likert scale, which read at a 5th grade level. Child-level variables will include age, sex (as a biological variable), race, and ethnicity. To estimate pilot effectiveness for future power calculations, our primary outcome will be child vaccination status at season's end (March 30th), defined in a binary manner (receipt of ≥ 1 dose by season's end versus unvaccinated). The investigators chose this definition as our pilot data found parental vaccine hesitancy increased a child's risk of influenza non-vaccination but did not increase their risk of partial vaccination (vs. full).
Analyses, Sample Size, & Calculations: The investigators will calculate descriptive statistics of caregivers' demographics and vaccine hesitancy scores. For our primary outcome of pilot effectiveness, the investigators will use an intention-to-treat approach comparing the proportion of children of caregivers randomized to digital stories versus literacy videos who received 1 or more vaccine dose by season's end. The investigators will fit univariable and multivariable logistic regression models to explore associations with caregiver demographics and parental vaccine hesitancy scores. To address instances of video non-viewing, the investigators will repeat these analyses between caregivers whose unique Digital Story links were accessed - i.e., presumably viewed - and caregivers in the control group.
The investigators will then describe intervention caregivers' perceptions of feasibility, acceptability, and appropriateness; as set cut points for acceptability and appropriateness do not yet exist, the investigators plan to use ≥ 70% agreement as with prior work by our group. Using these cut points, the investigators will fit univariable and multivariable logistic regression models to estimate the association between covariates (e.g., demographics, vaccine hesitancy score) and whether a caregiver perceived the intervention as feasible, acceptable, or appropriate.
The investigators performed sample size calculations based on the precision with which the investigators could estimate the treatment effect, as measured by the difference in proportion vaccinating between intervention and control arms. The investigators hypothesize our estimated pilot effect size will be ≥ 0.10, or modest for a vaccination trial. With n = 200, the investigators expect to attain a margin of error (equal to one half of the width of a 95% confidence interval) for the estimated treatment effect of approximately 0.14). All analyses will be performed in R.
SA3.5. Limitations & Alternative Approaches: (1) Poor recruitment. The investigators collected pilot data in the same clinic and 2 others from 255 caregivers of 2 year-olds in 6 months. By extending inclusion criteria to ages 6 months to 5 years, the investigators are confident the investigators can recruit 200 dyads. If necessary, the work will continue during a second influenza season (10/1/2025 - 3/31/2026) to ensure the investigators meet recruitment goals. (2) Poor perceived acceptability, appropriateness, or feasibility. If our analyses suggest the investigators need to improve intervention feasibility, acceptability, or appropriateness, the investigators will work with community and clinical stakeholders to iteratively modify and pilot-test the adapted intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80205
- Denver Health Eastside Clinic
-
Denver, Colorado, United States, 80207
- Denver Health Park Hill Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Caregivers of a child who is empaneled at Denver Health (e.g. had 1 well child visit in last 18 months)
- Child will be aged 6 months to 5 years during the influenza season in which the trial will be conducted (season 1: 10/1/24-3/31/25; season 2 (if needed): 10/1/25-3/31/26)
- Child has no medical contraindications to vaccination (e.g., severe allergy to one of the vaccine ingredients, history of Guillan-Barre Syndrome)
Exclusion Criteria:
- Caregivers whose first language is not English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Digital storytelling group
Caregivers will receive a series of digital stories by text message designed to increase influenza vaccine confidence.
|
Caregivers will receive text messages with embedded digital stories and messaging to encourage influenza vaccination.
|
|
No Intervention: Control group
Caregivers will receive standard care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Child influenza vaccination status at influenza season's end (defined as March 31, 2025 for season 1 and March 31, 2026 for season 2 if a 2nd season of recruitment is necessary)
Time Frame: Baseline, up to 1 year
|
Binary variable: Vaccinated (if a child received 1 or more doses of influenza vaccine), Unvaccinated (if a child received 0 doses)
|
Baseline, up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention Feasibility
Time Frame: through study completion, an average of 1 year
|
Feasibility of digital storytelling among caregivers, assessed per validated survey instrument published by Bryan Weiner and colleagues in Implementation Science in 2017: "Psychometric Assessment of three newly developed implementation outcome measures"
|
through study completion, an average of 1 year
|
|
Intervention Acceptability
Time Frame: through study completion, an average of 1 year
|
Acceptability of digital storytelling among caregivers, assessed per validated survey instrument published by Bryan Weiner and colleagues in Implementation Science in 2017: "Psychometric Assessment of three newly developed implementation outcome measures"
|
through study completion, an average of 1 year
|
|
Intervention Appropriateness
Time Frame: through study completion, an average of 1 year
|
Appropriateness of digital storytelling among caregivers, assessed per validated survey instrument published by Bryan Weiner and colleagues in Implementation Science in 2017: "Psychometric Assessment of three newly developed implementation outcome measures"
|
through study completion, an average of 1 year
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 21-3985
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
Canadian Immunization Research NetworkCHU de Quebec-Universite Laval; McGill University Health Centre/Research Institute... and other collaboratorsActive, not recruitingAvian Influenza | H5N1 Virus | H5N1 Influenza | Avian Influenza A VirusCanada
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on Digital storytelling
-
The Hong Kong Polytechnic UniversityHong Kong Children's Hospital; Research Grants Council, Hong KongRecruiting
-
Kocaeli UniversityGazi UniversityCompletedCancer | Child, Only | Symptoms and Signs | NarrationTurkey (Türkiye)
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Hennepin... and other collaboratorsCompletedType2 DiabetesUnited States
-
Arizona State UniversityNational Institute on Minority Health and Health Disparities (NIMHD)CompletedHealth Knowledge, Attitudes, Practice | Human Papilloma Virus | Preventable Disease, Vaccine | NarrativeUnited States
-
Mayo ClinicHennepin Healthcare Research Institute; Mountain Park Health CenterCompleted
-
Mayo ClinicCompletedType2 DiabetesUnited States
-
Bozok UniversityNot yet recruitingPrimiparous Pregnant Women
-
Gazi UniversityCompletedNursing Students | Role Playing | Ethical Sensitivities | Analyses, Ethical | Digital Storytelling | Ethics Education | Ethical BehaviorTurkey